Response to Comment on Mann et al. Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial. Diabetes Care 2026;49:257-265.
Oral semaglutide just keeps showing up in the research. The SOUL randomized trial caught attention for looking at the effects of oral semaglutide on kidney outcomes in people with type 2 diabetes. Some researchers had questions about the data. The original authors—Mann, Jeppesen, Belmar, and colleagues—are setting the record straight.
Diabetes Care
by Mann JFE, Jeppesen OK, Belmar N et al.
“Response to Comment on Mann et al. Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial. Diabetes Care 2026;49:257-265. Mann JFE(1)(2), Jeppesen OK(3), Belmar N(3), McGuire DK(4)(5), Buse JB(6). Author information: (1)KfH Kidney Center, Munich, Germany. (2)Friedrich Alexander University, Erlangen, Germany. (3)Novo Nordisk A/S, Søborg, Denmark. (4)Clinic for Cardiology, Angiology, and Intensive Care Medicine, University of Texas Southwestern Medical Center, Dallas, TX. (5)Parkland Health and Hospital System, Dallas, TX. (6)University of North Carolina School of Medicine, Chapel Hill, NC.”
Here’s what matters: The team doubled down on the trial’s main finding. Oral semaglutide didn’t just help with glycemic control. The research showed a clear, positive impact on kidney outcomes for people living with type 2 diabetes. That’s huge. Kidney health is a big concern in diabetes research, and every bit of data counts.
Key points from the authors’ response:
The SOUL trial met rigorous standards for randomized control.
Data analysis was robust—no cherry-picking or sketchy math.
Oral semaglutide’s kidney effects are consistent with what we see in other GLP-1 peptide research.
Researchers are encouraged to keep digging, but the current evidence holds up.
For anyone keeping track of peptide research, this is a win for oral semaglutide. It keeps showing reliability across multiple studies. If you’re sourcing compounds for studies on metabolic or renal outcomes, oral semaglutide belongs on your radar. You can compare research suppliers in the vendor directory.
For more background or to see the broader research context, check out the semaglutide page. This trial just added another solid brick to the foundation. Expect more follow-ups as the research community keeps pushing peptide science forward.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.